Streetbeat News

Revenues

OGN

Organon has reaffirmed its 2023 revenue and adjusted EBITDA guidance, indicating stability in its financial outlook. Additionally, the company projects low-single-digit revenue growth for 2024 on a constant currency basis, suggesting a cautious but positive outlook for the near future.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:42 pm

BABA

BIDU

NVDA

TCEHY

Nvidia Corp (NVDA) faces challenges in the Chinese market due to U.S. regulations barring high-performance AI chip sales. Major Chinese cloud companies like Alibaba (BABA) and Tencent (TCEHY) plan to reduce Nvidia chip orders, turning to local alternatives and in-house developments. Baidu (BIDU) and ByteDance are also shifting towards domestic producers like Huawei. Despite this, Nvidia sold over $1 billion of modified chips in China in 2023 and is developing new AI chips like the H20 for the Chinese market, set for production in Q2 2024. Nvidia's stock saw a slight increase on Monday.

Portfolio Pulse from Anusuya Lahiri

January 08, 2024 | 12:40 pm

RCM

R1 RCM forecasts Q4 revenue of $563M-$567M, below the consensus estimate of $585.82M. The company anticipates GAAP operating income of $36M-$39M, a GAAP net loss of $(8)M-$(10)M, and adjusted EBITDA of $163M-$166M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:39 pm

NUS

Nu Skin Enterprises has reported preliminary Q4 revenue that is slightly above their guidance. The company will announce full financial results on February 14.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:38 pm

OSW

OneSpaWorld (OSW) has released preliminary Q4 total revenue estimates of $193M-$198M, slightly below the estimated $198.36M. For FY24, the company expects total revenues of $850M-$870M, which is within the range of the estimated $857.29M. Additionally, the company anticipates a 45% increase in revenues to $792M-$797M for fiscal 2022, up from $546.3M in the previous year.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:36 pm

REGN

Medison Pharma has entered into an agreement with Regeneron Pharmaceuticals to commercialize Libtayo, a cancer treatment drug, in multiple countries. This partnership could potentially expand the market reach of Libtayo and enhance its sales, benefiting Regeneron's revenue stream and market presence in the oncology sector.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:32 pm

VVOS

Vivos Therapeutics reports a 600% increase in new dentist inquiries to participate in its Integrated Practice program and a 38% rise in signed dentist enrollment contracts over Q3.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:31 pm

BFI

BurgerFi International reported preliminary Q4 revenue of $42M, surpassing the $40M estimate, and restaurant sales of $65M. For fiscal year 2023, total store revenue was about $170M with systemwide restaurant sales around $275M. However, same-store sales decreased by 3% at Anthony's and 9% at BurgerFi in Q4, and by 1% and 7% respectively for the full year. The company reiterated its Adjusted EBITDA guidance of $6-8M and capital expenditures of approximately $2M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:31 pm

NPCE

NeuroPace, Inc. has announced preliminary Q4 revenue of $17.5M-$18M, surpassing the $15.79M estimate. Additionally, the company forecasts 2023 revenue to be between $64.9M and $65.4M, which is also above the estimated $63.01M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:30 pm

MRKR

Marker Therapeutics provided updates on its clinical programs and pipeline prioritization, focusing on advancing multiple product candidates. The company is prioritizing its resources to accelerate the development of its most promising therapies. Specific updates on clinical trials or regulatory milestones were not provided in the news.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:29 pm